Formycon's FYB208 biosimilar achieves key milestone in dupilumab development

Formycon AG has reached a key milestone in developing its new drug candidate, FYB208. The company announced it has completed a Technical Proof of Similarity (TPoS), confirming that FYB208 closely matches the reference medicine Dupixent. This progress could speed up the drug's path to approval and expand treatment options for patients with inflammatory conditions.

FYB208 is a biosimilar targeting dupilumab, the active ingredient in Dupixent. This compound blocks signalling pathways for interleukin-4 (IL-4) and IL-13, which play a role in inflammatory diseases such as COPD, asthma, and atopic dermatitis. By developing a biosimilar, Formycon aims to make dupilumab-based treatments more accessible, particularly for COPD patients.

The completion of the TPoS demonstrates that FYB208 is highly comparable to Dupixent in analytical testing. Formycon believes this result could eliminate the need for a full comparative efficacy study, such as a Phase III trial. If approved, this would allow the company to advance FYB208 more quickly through the regulatory process.

Dr. Andreas Seidl, Chief Scientific Officer at Formycon, highlighted the significance of this achievement. He noted that finishing preclinical development marks another major step forward for the company. The drug's target market is also expanding rapidly, driven by the growing use of dupilumab in treating various inflammatory conditions.

Formycon's progress with FYB208 could lead to faster approval and broader availability of dupilumab-based therapies. The biosimilar's high analytical similarity to Dupixent may streamline development, reducing the need for extensive additional trials. If successful, the drug would offer an alternative for patients relying on Dupixent for conditions like COPD, asthma, and atopic dermatitis.